Racial and ethnic disparities in biologic prescriptions for asthma in the United States

Abstract

In the United States, morbidity and mortality from asthma are declining, but racial and ethnic differences in asthma burden remain unresolved.1 Compared with White patients, individuals of underrepresented backgrounds have a higher prevalence of moderate-to-severe persistent asthma, difficult-to-treat asthma, and emergency room utilization for asthma care.2,3 Asthma biologics that target type 2 airway inflammation lessen disease burden, reduce asthma exacerbation risk, and improve quality-of-life metrics.